Holen Sie sich die Stockscreener-App
1.735
0.87%
0.015
Schlusskurs vom Vortag:
$1.72
Offen:
$1.73
24-Stunden-Volumen:
1.10M
Relative Volume:
0.92
Marktkapitalisierung:
$123.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-192.96M
KGV:
-0.6196
EPS:
-2.8
Netto-Cashflow:
$-167.04M
1W Leistung:
-11.93%
1M Leistung:
-27.41%
6M Leistung:
-63.40%
1J Leistung:
-25.54%
1-Tages-Spanne:
$1.67
$1.77
1-Wochen-Bereich:
$1.67
$2.00
52-Wochen-Spanne:
$1.67
$11.48
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Firmenname
Ventyx Biosciences Inc
Sektor
Branche
Telefon
(858) 945-2393
Adresse
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Vergleichen Sie VTYX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| VTYX | 1.735 | 123.04M | 0 | -192.96M | -167.04M | -2.80 |
| VRTX | 449.99 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.40 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 593.04 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.04 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.32 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-19 | Eingeleitet | Goldman | Buy |
| 2022-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-07 | Eingeleitet | Stifel | Buy |
| 2022-09-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-09 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-02-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-15 | Eingeleitet | Jefferies | Buy |
| 2021-11-15 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Ventyx Biosciences Inc Aktie (VTYX) Neueste Nachrichten
Thinking about buying stock in Solid Power, Crowdstrike Holdings - GuruFocus.com
Ventyx Biosciences stock hits 52-week low at $1.78 amid market shifts - Investing.com Australia
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully - Simply Wall St
Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress - Yahoo Finance
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences - The Manila Times
Ventyx Biosciences (NASDAQ:VTYX) Earns "Neutral" Rating from HC Wainwright - MarketBeat
Ventyx Biosciences’ (VTYX) “Outperform” Rating Reiterated at Oppenheimer - Defense World
Ventyx Biosciences (NASDAQ:VTYX) Given "Outperform" Rating at Oppenheimer - MarketBeat
Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress - The Manila Times
Vanguard Group Inc's Strategic Acquisition in Ventyx Biosciences Inc - GuruFocus.com
Ventyx Biosciences: Ready To Escape "The Crash Cycle" (NASDAQ:VTYX) - Seeking Alpha
Thinking about buying stock in QuickLogic, Ventyx Biosciences, D - GuruFocus.com
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts - Markets Insider
Brokerages Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $8.29 - MarketBeat
HC Wainwright Cuts Earnings Estimates for Ventyx Biosciences - MarketBeat
Ventyx Biosciences maintains Neutral rating from H.C. Wainwright - Investing.com
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 in Ulcerative Colitis at UEG Week 2024 - Marketscreener.com
Ventyx Biosciences maintains Neutral rating from H.C. Wainwright By Investing.com - Investing.com UK
Ventyx Biosciences Presents New 52-Week Results from the - GlobeNewswire
Ventyx Biosciences (NASDAQ:VTYX) Given "Neutral" Rating at HC Wainwright - MarketBeat
Ventyx reports positive Phase 2 ulcerative colitis trial data - Investing.com
Ventyx reports positive Phase 2 ulcerative colitis trial data By Investing.com - Investing.com Canada
VTYX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Ventyx Biosciences Inc (VTYX) stock analysis: A comprehensive overview - US Post News
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024 - The Manila Times
Did Ventyx Biosciences Inc (VTYX) perform well in the last session? - US Post News
An analyst sees good growth prospects for Ventyx Biosciences Inc (VTYX) - SETE News
Sanofi Invests $27M in Ventyx Bio - San Diego Business Journal
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Ventyx Biosciences Inc (VTYX) may enjoy gains as insiders got busy in the recent days - Knox Daily
Is Ventyx Biosciences Inc (VTYX) a good investment opportunity? - US Post News
Gaining Ground: Ventyx Biosciences Inc (VTYX) Closes Lower at 2.31, Down -2.12 - The Dwinnex
Take off with Ventyx Biosciences Inc (VTYX): Get ready for trading - SETE News
VTYX Stock Rises on Strategic Equity Investment Deal With SNY - MSN
Deerfield Management Company L.P. Series C Buys 2,287,570 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - MarketBeat
Stock Surge: Ventyx Biosciences Inc (VTYX) Closes at 2.39, Marking a -2.85 Increase/Decrease - The Dwinnex
Ventyx Biosciences, Inc. (NASDAQ:VTYX) to Post FY2024 Earnings of ($2.13) Per Share, HC Wainwright Forecasts - MarketBeat
Sanofi’s $27 Million Investment in Ventyx Biosciences - Global Legal Chronicle
Adversity is less terrifying than hope: Ventyx Biosciences Inc (VTYX) - SETE News
Ventyx Biosciences retains stock target, neutral rating despite Sanofi's $27M stake - Investing.com
Benjamin F. Edwards & Company Inc. Buys 16,858 Shares of Twist Bioscience Co. (NASDAQ:TWST) - MarketBeat
Ventyx deal a sign of Sanofi’s growing interest neuro-immunology? - BioCentury
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal - Pharmaceutical Technology
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences - MSN
Ventyx Biosciences Inc (VTYX) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Ventyx Biosciences (NASDAQ:VTYX) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Ventyx stock climbs 8% on $27M Sanofi investment - MSN
Thoughtworks (NASDAQ:TWKS) Sees Large Volume Increase - Defense World
VTYX’s Q2 earnings predictions: What the experts say - US Post News
Sanofi investment in Ventyx shows VTX3232 interest, says H.C. Wainwright - TipRanks
Finanzdaten der Ventyx Biosciences Inc-Aktie (VTYX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ventyx Biosciences Inc-Aktie (VTYX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Krueger Christopher W | CHIEF BUSINESS OFFICER |
Apr 02 '24 |
Sale |
5.40 |
1,651 |
8,921 |
284,999 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Apr 02 '24 |
Sale |
5.40 |
1,651 |
8,921 |
264,998 |
| Mohan Raju | CEO AND PRESIDENT |
Apr 02 '24 |
Sale |
5.40 |
4,312 |
23,299 |
1,578,250 |
| Auster Martin | CHIEF FINANCIAL OFFICER |
Apr 02 '24 |
Sale |
5.40 |
1,405 |
7,592 |
24,303 |
| Krueger Christopher W | CHIEF BUSINESS OFFICER |
Mar 28 '24 |
Option Exercise |
0.00 |
4,531 |
0 |
286,650 |
| Auster Martin | CHIEF FINANCIAL OFFICER |
Mar 28 '24 |
Option Exercise |
0.00 |
4,531 |
0 |
25,708 |
| Mohan Raju | CEO AND PRESIDENT |
Mar 28 '24 |
Option Exercise |
0.00 |
11,843 |
0 |
1,582,562 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Mar 28 '24 |
Option Exercise |
0.00 |
4,531 |
0 |
266,649 |
| Nuss John | Chief Scientific Officer |
Dec 20 '23 |
Sale |
2.12 |
17,628 |
37,334 |
262,118 |
| Krueger Christopher W | Chief Business Officer |
Dec 20 '23 |
Sale |
2.12 |
5,293 |
11,210 |
282,119 |
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):